You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝達藥業(300558.SZ):上半年淨利潤2.24億元 同比增長51.00%
格隆匯 08-05 20:08

格隆匯8月5日丨貝達藥業(300558.SZ)公佈2024年半年度報吿,報吿期內,公司實現營業收入15.01億元,同比增長14.22%;歸屬於上市公司股東淨利潤2.24億元,同比增長51.00%;歸屬於上市公司股東的扣除非經常性損益的淨利潤為2.17億元,同比增長144.98%;經營活動產生的現金流量淨額5.22億元,同比增長44.77%。

2024年上半年,公司研發投入達到38,185.33萬元,持續的研發投入陸續取得階段性成果,推動公司管線成長。報吿期內,美國FDA完成有關貝美納“擬用於ALK陽性的局部晚期或轉移性NSCLC患者的治療”(一線治療適應症)上市許可申請相關申報文件的審查,確定申請材料完整,審查工作順利推進中。公司自主研發的CDK4/6抑制劑BPI-16350項目“聯合氟維司羣對比安慰劑聯合氟維司羣治療既往接受內分泌治療後進展的HR+/HER2-的局部晚期、復發或轉移性乳腺癌受試者”取得Ⅲ期臨牀研究報吿,上市許可申請於2024年5月獲得NMPA受理,有望為乳腺癌患者帶來新的方案選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account